linjc16/ctgov huggingface dataset:
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

Study Overview
=================
Brief Summary
-----------------
The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).

Official Title
-----------------
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

Conditions
-----------------
Non-Small Cell Lung Carcinoma, Venous Thromboembolism

Intervention / Treatment
-----------------
* Procedure: Blood sample withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically or cytologically confirmed diagnosis of NSCLC. normal serum bilirubin informed concent to participate in the study Exclusion Criteria: anticoagulant therapy infectious disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Blood sample withdrawal|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung cancer, Thrombosis, Hypercoagulable
Endoscopic Characterization of Colorectal Neoplasia With the Different Published Classifications: a Prospective Comparative Study

Study Overview
=================
Brief Summary
-----------------
Endoscopic characterization of colorectal lesions has become essential to predict histology and choose the best therapeutic strategy. We have created the CONECCT classification grouping all the endoscopic criteria already published in a single table. To validate this classification, we carried out this comparative study evaluating the endoscopic characterization performance of all recognized classifications and CONECCT in terms of inter-observer agreement and histological prediction.

Official Title
-----------------
Endoscopic Characterization of Colorectal Neoplasia With the Different Published Classifications: a Prospective Comparative Study Involving Gastroenterologists From Trainees to Experts

Conditions
-----------------
ENDOSCOPIC CHARACTERIZATION

Intervention / Treatment
-----------------
* Procedure: DIGESTIVE ENDOSCOPY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: none Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of inter observer agreement in the use of current endoscopic classifications |  | 1 year |
Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analyze the correlation between intra-abdominal view and patient recovery in secondary peritonitis, and to create a new classification based on these results. Additionally, a variety of inflammatory markers from blood samples will be collected in order to analyze their correlation with patient outcomes.

Official Title
-----------------
Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery

Conditions
-----------------
Peritonitis

Intervention / Treatment
-----------------
* Other: No intervention, merely observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients > 18 years old operated for complicated intra-abdominal infection Exclusion Criteria: another diagnosis requiring ICU level care at the same time acute pancreatitis acute mesenteric ischaemia due to occlusion in superior mesenteric artery or vein peritonitis due to timely diagnosed trauma missing informed consent or inability to understand it

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention, merely observational|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death within 90 days of primary operation for diffuse peritonitis | 90 days | 
| ICU admission | Intensive Care Unit admission and length of ICU treatment | 90 days | 
| Length of hospitalization | Days in hospital postoperatively | 90 days | 
| Reoperations | Reoperations needed postoperatively | 90 days | 
| Complications | Postoperative complications according to Clavien-Dindo classification | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peritonitis, Inflammatory Markers, Patient Outcome Assessment, Classification, Multiple Organ Failure, Intraabdominal Infections
Corneal Astigmatism Measurement Study

Study Overview
=================
Brief Summary
-----------------
To assess which commercially available measurement device is most accurate in measuring low (< 1.0 D) degrees of corneal astigmatism.

Conditions
-----------------
Astigmatism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50 years of age and older Proof of eye exam within the last 3 months Corneal astigmatism of <1.0 diopter Exclusion Criteria: Prior history of refractive or corneal surgery Corneal trauma/disease Intraocular surgery

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Measurement device | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of corneal power |  | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Corneal astigmatism, Low diopter, Corneal measurement, Corneal astigmatism < 1 Diopter
Effects of Local Insulin on Wound Angiogenesis

Study Overview
=================
Brief Summary
-----------------
Randomized, split plot, double-blind, placebo controlled trial. Half of the wounds surface was applied daily with insulin and the other half with saline solution as placebo. Biopsy specimens of the two sides were obtained on days 0 and 14. Number of blood vessels will be evaluated as main outcome.

Detailed Description
-----------------
Randomized, split plot, double-blind, placebo controlled trial. Non-diabetic patients with full-thickness wounds will be treated in the following manner: in half of the surface insulin will be applied in a daily basis, on the other half, saline solution will be used as placebo. Biopsy specimens of both sides will be obtained on days 0 and 14. Number of blood vessels will be evaluated as main outcome.

Official Title
-----------------
Effects of Local Insulin on Angiogenesis in Acute Wounds in Non-diabetic Patients

Conditions
-----------------
Angiogenesis

Intervention / Treatment
-----------------
* Drug: Insulin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nondiabetic patients with full-thickness acute wounds Exclusion Criteria: Diabetic patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Insulin<br>Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized. | Drug: Insulin<br>* Half of the wound surface was treated daily with 10 units of intermediate insulin.<br>|
| Placebo Comparator: Placebo<br>Half of the wound surface was treated daily with normal saline. Allocation was randomized. | Drug: Placebo<br>* Half of the wound surface was treated daily with 0.1 cc of normal saline.<br>* Other names: Normal saline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of blood vessels | In a biopsy taken at baseline, blood vessels will be counted | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoglycaemia | Presence of capillary blood glucose of <60 mg/dl | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fibroplasia, Blood vessel, Wound healing, Insulin
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

Study Overview
=================
Brief Summary
-----------------
Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods

Official Title
-----------------
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy Male Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: dabigatran etexilate
* Drug: Ticagrelor
* Drug: Ticagrelor
* Drug: dabigatran etexilate
* Drug: dabigatran etexilate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Healthy male subjects Exclusion criteria: Any relevant deviation from healthy conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test 2 (part 3)<br>low dose dabigatran + high dose ticagrelor | Drug: Ticagrelor<br>* high dose ticagrelor<br>Drug: dabigatran etexilate<br>* medium dose dabigatran<br>|
| Active Comparator: Test 1 (part 1 + 2)<br>high dose ticagrelor | Drug: Ticagrelor<br>* high dose ticagrelor<br>|
| Experimental: Reference 1 (part 1 + 2)<br>medium dose dabigatran | Drug: dabigatran etexilate<br>* medium dose dabigatran<br>|
| Experimental: Reference 2 (part 3)<br>low dose dabigatran | Drug: dabigatran etexilate<br>* low dose dabigatran<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) | Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran. | -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours | 
| Total Dabigatran: Maximum Measured Concentration (Cmax) | Maximum measured concentration of total dabigatran in plasma, per period. | -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Drug Related Adverse Events | The number of participants with drug related adverse events | From screening until the end-of-study examination |
Assess the Effect of Treating Periodontal Disease on Cardiovascular Function in Young Adults

Study Overview
=================
Brief Summary
-----------------
We propose to examine a population of Native Americans who have had little or no dental care, and to determine if periodontal disease is associated with early signs of vascular dysfunction or systemic inflammation. We then propose to treat the periodontitis and re-evaluate vascular function. We will determine if gingivitis or mild/moderate periodontitis is associated with detectable vascular dysfunction. Microbial metagenomics will be correlated with vascular function.

Official Title
-----------------
Oral Flora, Periodontitis, and Vascular Dysfunction in Young Native Americans.

Conditions
-----------------
Periodontal Disease, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Indian/Alaskan Natives seeking health care at the Indian Health Council, Inc. Males and females aged 21-40 years. Exclusion criteria: Recent (within 6 months) periodontal treatment History of high blood pressure or existing heart disease Xerostomia Currently receiving treatment for cancer Currently taking anti-inflammatory medications (except H2 blockers, statins, or medications that can affect periodontal status Immunosuppressed due to medication or HIV infection, or presence of active infection such as hepatitis or tuberculosis Fewer than 20 teeth in functional dentition, excluding third molars, or other gross oral pathology

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of bacterial populations in periodontal samples before and after standard periodontal treatment, stratified by severity of gum disease, using microbial metagenomics analysis. | The study will assess if periodontal bacterial flora differ in patients with healthy gums, mild, or severe periodontal disease. | Time of enrollment and at 6 week follow up visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Periodontal disease, Atherosclerosis, Oral Pathogens, Native Americans, Inflammatory cytokines, Microbial metagenomics
Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients

Study Overview
=================
Brief Summary
-----------------
Different tools may be used to monitor the efficacy of home mechanical ventilation. Investigators aimed to compare the prognostic value of the different data obtained by capno-oxymetry in a mechanical ventilated neuromuscular disease's population.

Detailed Description
-----------------
Home mechanical ventilation (HMV) is used to treat hypoventilation, and its efficacy is mostly assessed by daytime blood gases and nocturnal oxymetry (SpO2). Transcutaneous CO2 measure (TcCO2) has shown higher sensitivity than SpO2 to detect hypoventilation in neuromuscular diseases (NMD) patients. No data exist on the prognostic value of these techniques to monitor mechanical ventilated NMD patients. Basing on retrospective data review, investigators aimed to compare the prognostic value of the data obtained using different tools to assess residual hypoventilation in the cohort of ventilated NMD patients followed at our reference center.

Official Title
-----------------
Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients

Conditions
-----------------
Home Mechanical Ventilation, Neuromuscular Disease

Intervention / Treatment
-----------------
* Device: Capno-oxymetry monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neuromuscular disease age ≥18 years mechanically ventilated capno-oxymetry performed between 2009 and 2011 Exclusion Criteria: Long-term oxygen therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first ICU admission | Time to first ICU admission | 6 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Time to death | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nocturnal hypoventilation, capno-oxymetry
Association Between Pococyturia and Pre-eclampsia Severity

Study Overview
=================
Brief Summary
-----------------
Pre-eclampsia is an hypertensive disorder appearing during pregnancy, inducing serious maternal, fetal and neonatal mortality and morbidity. Twenty four hours proteinuria is a key element to define pre-eclampsia severity but is delaying the result by 24 hours and constraining for the patient. A simple and rapid indicator for severe preeclampsia would help clinicians to make appropriate decision in patient management. We hypothesized that urinary podocyturia is correlated to preeclampsia severity. This is a prospective, non-interventional, monocentric study.

Official Title
-----------------
Prospective Study : Association Between Pococyturia and Pre-eclampsia Severity

Conditions
-----------------
Pre-Eclampsia

Intervention / Treatment
-----------------
* Other: Dosage of urinary podocyturia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women aged 18 years or more single pregnancy admission for pre-eclampsia patient receiving information and non-opposition to participate Exclusion Criteria: multiple pregnancy in utero fetal demise excepted if associated with pre-eclampsia antecedent of nephropathy fetal malformation, chromosomal anomalies inability to understand information provided prisoner or under administrative supervision

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pre-eclampsia<br>Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant | Other: Dosage of urinary podocyturia<br>* Dosage of urinary podocyturia at admission, delivery and post-partum visit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of pre-eclampsia | Severe preeclampsia is defined by preeclampsia with at least one of the following criteria : severe hypertension (PAS ≥ 160 mmHg et/ou PAD ≥ 110 mmHg) Renal impairment with: oliguria <500 ml / 24h or creatinine> 135 μmol / L or proteinuria> 5 g/d acute lung edema or persistent epigastric bar or HELLP syndrome eclampsia or rebellious neurological disorders (visual disturbances, polykinetic ROT, headache), thrombocytopenia <100 G / L Retro Placental Hematoma (HRP) or fetal repercussion. | at childbirth (maximum 10 months) |
Q-Switched Nd:YAG in Macular Amyloidosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Q-Switched Nd:YAG Laser therapy are effective in reduction of Cutaneous macular amyloidosis.

Detailed Description
-----------------
We treat the macular amyloidosis cases by Q-Switched Nd:YAG Laser and compare the before and after treatment situation by the photos and colorimetric assessment.

Conditions
-----------------
Macular Amyloidosis

Intervention / Treatment
-----------------
* Device: Laser Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Macular amyloidosis confirmed cases Exclusion Criteria: Pregnancy and breast feeding Over 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Laser Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual and colorimetric assessment |  |  |